Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by longterm56on Dec 12, 2021 7:44pm
108 Views
Post# 34223689

RE:RE:RE:RE:RE:Next week?

RE:RE:RE:RE:RE:Next week?Hey palinc ... I hope you are right.  But I'm curious, is this pure conjecture or have you "heard something"?

   -LT


palinc2000 wrote: I think I am leaning towards a Nash partnership but hey I would welcome any positive news .....I am also looking at the calendar and I think Dec 15 might be the last day in 2021nto release good news and leave enough time for the market to digest it and give it the attention it deserves before the Holidays

SPCEO1 wrote: Are you thinking NASH and/or cancer partnership news? New drug acquisition? I could see there being cancer partnership news from China or Western drug companies even before we get the news of how the phase 1a ended.

Celarly, the options grant tells us some good news is coming. It does not tell us exactly when it will be announced, what that news might be or how significant the market might view it, but some degree of good news is on the way.

It seems to me there is a good chance they have now seen some sign of tumor regression at the roughly 2x the normal Docetaxel dose. If they were fortunate to get at least two sortilin overexpressing patients in that dosage level and they had two different types of cancer and they saw responses in both, than that would be very good news indeed.

palinc2000 wrote: Positive news could come from other fronts also ......


SPCEO1 wrote: If the trial is going to go into January, they really should give us an update prior to Christmas.

palinc2000 wrote: Crossing my fingers for positive news ,,,

 

 

 




<< Previous
Bullboard Posts
Next >>